Clinical Trial Update: Glofitamab in Chinese Patients With R/R DLBCL

View source ↗

Summary

Clinical trial update for glofitamab in Chinese patients with relapsed/refractory diffuse large B-cell lymphoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: DLBCL - Diffuse Large B Cell Lymphoma | Status: RECRUITING